Pure Global

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors - Trial NCT06143735

Access comprehensive clinical trial information for NCT06143735 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 99 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06143735
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06143735
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
A Randomized, Multicenter, Exploratory Clinical Study for The Primary And Secondary Prevention of Febrile Neutropenia (FN) With Efbemalenograstim Alfa in Patients With Non-small Cell Lung Cancer (NSCLC) at Moderate Risk Undergoing Chemotherapy Regimens With Associated Risk Factors

Study Focus

Efgbemalenograstim alfa

Interventional

drug

Sponsor & Location

Tianjin Medical University Cancer Institute and Hospital

Zhengzhou,Wuhan,Hohhot,Shenyang,Xi'an,Jinan,Chengdu,Chengdu,Ningbo,Tianjin, China

Timeline & Enrollment

Phase 2

Dec 31, 2023

Jun 30, 2026

99 participants

Primary Outcome

The incidence rate of Grade ≥3 ANC reduction

Summary

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the
 prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients
 at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06143735

Non-Device Trial